Alkermes (STU:8AK) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8AK Alkermes PLC STU:8AK
65 GF Score
Price €46.42
GF Value €28.17
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Alkermes Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:8AK vs LQDA, LNTH, HIMS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alkermes Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Short Interest distribution charts can be found below:

* The bar in red indicates where Alkermes's Short Interest falls into.


STU:8AK
65GF Score
Alkermes PLC STU:8AK
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alkermes (STU:8AK) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of €46.42 is trading 64.8% above its estimated GF Value™ of €28.17. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for STU:8AK:

  • Short Interest:
  • GF Value™: €28.17 vs. price of €46.42 (64.8% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the STU:8AK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkermes Business Description

Other Exchanges ALKS:USA8AK:Germany
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
65GF Score

Get the complete analysis for STU:8AK

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.42
Price
€28.17
GF Value